10
Participants
Start Date
July 27, 2017
Primary Completion Date
May 7, 2020
Study Completion Date
May 7, 2020
Pegvisomant
Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (\<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
University of Alberta Hospital, Edmonton
St. Joseph Health Care London, London
The Ottawa Hospital, Ottawa
McGill University Health Centre, Montreal
Centre hospitalier universitaire de Québec-Université Laval, Québec
Unity Health Toronto
OTHER